Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Aplastic anemia.

× No keyword cloud information.

23 in total

1. Guidelines for the diagnosis and management of acquired aplastic anaemia.

Authors: J C W Marsh; S E Ball; P Darbyshire; E C Gordon-Smith; A J Keidan; A Martin; S R McCann; J Mercieca; D Oscier; A W W Roques; J A L Yin
Journal: Br J Haematol Date: 2003-12 Impact factor: 6.998

2. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO).

Authors: A Bacigalupo; B Bruno; P Saracco; E Di Bona; A Locasciulli; F Locatelli; A Gabbas; C Dufour; W Arcese; G Testi; G Broccia; M Carotenuto; P Coser; T Barbui; P Leoni; A Ferster
Journal: Blood Date: 2000-03-15 Impact factor: 22.113

3. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Authors: E Di Bona; F Rodeghiero; B Bruno; A Gabbas; P Foa; A Locasciulli; C Rosanelli; L Camba; P Saracco; A Lippi; A P Iori; F Porta; G De Rossi; B Comotti; P Iacopino; C Dufour; A Bacigalupo; V De Rossi
Journal: Br J Haematol Date: 1999-11 Impact factor: 6.998

4. Lack of in vitro colony (CFUC) formation and myelosuppressive activity in patients with severe aplastic anemia after autologous hematologic reconstitution.

Authors: A Bacigalupo; M Podesta'; M R Raffo; G Piaggio; M T Van Lint; R Vimercati; V M Spriano; M Risso; A M Marmont
Journal: Exp Hematol Date: 1980-07 Impact factor: 3.084

Review 5. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience.

Authors: A Bacigalupo; R Brand; R Oneto; B Bruno; G Socié; J Passweg; A Locasciulli; M T Van Lint; A Tichelli; S McCann; J Marsh; P Ljungman; J Hows; P Marin; H Schrezenmeier
Journal: Semin Hematol Date: 2000-01 Impact factor: 3.851

6. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial.

Authors: F Locatelli; B Bruno; M Zecca; M T Van-Lint; S McCann; W Arcese; S Dallorso; P Di Bartolomeo; F Fagioli; A Locasciulli; M Lawler; A Bacigalupo
Journal: Blood Date: 2000-09-01 Impact factor: 22.113

7. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program.

Authors: Seiji Kojima; Takaharu Matsuyama; Shunichi Kato; Hisato Kigasawa; Ryoji Kobayashi; Atsushi Kikuta; Hisashi Sakamaki; Koichiro Ikuta; Masahiro Tsuchida; Yasutaka Hoshi; Yasuo Morishima; Yoshihisa Kodera
Journal: Blood Date: 2002-08-01 Impact factor: 22.113

8. Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation.

Authors: J Y Pierga; G Socie; E Gluckman; A Devergie; M Henry-Amar; A Bridier; T Girinsky; J Nguyen; J M Cosset
Journal: Radiother Oncol Date: 1994-01 Impact factor: 6.280

9. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease.

Authors: R S Hill; F B Petersen; R Storb; F R Appelbaum; K Doney; S Dahlberg; R Ramberg; E D Thomas
Journal: Blood Date: 1986-03 Impact factor: 22.113

10. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.

Authors: Norbert Frickhofen; Hermann Heimpel; Joachim P Kaltwasser; Hubert Schrezenmeier
Journal: Blood Date: 2002-10-10 Impact factor: 22.113

3 in total

1. MHC class II upregulation and colocalization with Fas in experimental models of immune-mediated bone marrow failure.

Authors: Andrew J Erie; Leigh Samsel; Tomoiku Takaku; Marie J Desierto; Keyvan Keyvanfar; J Philip McCoy; Neal S Young; Jichun Chen
Journal: Exp Hematol Date: 2011-05-13 Impact factor: 3.084

2. Proliferation and apoptosis of bone marrow CD4(+) T cells in patients with aplastic anemia and impacts of the secreted cytokines on hematopoietic stem cells from umbilical cord blood.

Authors: Miao Zheng; Hanying Sun; Jianfeng Zhou; Huizhen Xu; Lifang Huang; Wenli Liu
Journal: J Huazhong Univ Sci Technolog Med Sci Date: 2010-02-14

3. The role of the Th1 transcription factor T-bet in a mouse model of immune-mediated bone-marrow failure.

Authors: Yong Tang; Marie J Desierto; Jichun Chen; Neal S Young
Journal: Blood Date: 2009-11-10 Impact factor: 22.113

3 in total